Immunogen Design JMAG

Oct 15, 2024, 9:00 AM → Oct 16, 2024, 5:00 PM America/Chicago

Primary Objective of the JMAG: Coordination meeting to present an overview on the Vaccine Library approach going forward.  Update/presentation from the IDDL and HMRI consortium on the funded work packages.  Identify problems and potential solutions on project execution. Discussion on endpoints to complete virus families and work packages.

Tuesday, October 15

1 Welcome and introduction of participants

2 Welcome and introduction to ANL and overview of resources (Talk/presentation).

3 Overview and progress of the Disease X vaccine library approach and strategy-5 year objectives

4 Overview of high-level plans from HMRI, including resources and capacity for immunogen design

11:00 AM Coffee Break

5 Overview of high-level plans from IDDL, including resources and capacity for immunogen design

6 Process for coordination between IDDL and HMRI and within HMRI consortium (HMRI/IDDL). Database storage and controlled access. VIPNetX/ANL database

1:00 PM Lunch

Review of IDDL/HMRI workflow: from in silico design to in vitro validation: strategy, selection criteria, number of candidates, technology and timings

7 Review of process for immunogen design & down selection criteria

8 Review of process for immunogen design, antigen verification, structure confirmation & down selection criteria

9 Review of process for T-cell immunogen design, antigen verification & down selection criteria and update on work packages

3:00 PM Coffee Break

10 Review of ANL workflow and progress update

11 Review of Spillover program

6:30 PM Dinner at Barrel & Vine

Wednesday, October 16

12 Recap of day 1, objectives for day 2

Speakers: Ann-Muriel Steff, Tim Endy

13 Junin virus vaccine designs update: vaccine composition, immunogens, timings and number of designs and preclinical work

14 Lassa virus vaccine designs: immunogen design, progress with SK bio

Milestones/criteria for down-selection and/or optimization in immunogen design
• At the stage of immunogen design by HMRI & IDDL
• At the stage of transfer of the candidates to SK (i.e. elicitation of neutralizing antibodies and/or expression efficiency)
• Results to date

15 Update on H5N1 designs

10:15 AM Coffee Break

16 Patents and IP, tools for the Global South Discussion

17 Project Management Discussion

Reporting, JMAG, other CEPI follow-up (Polina)
Interactions with future developers

11:30 AM Lunch

18 Tour of ANL

Breakout Sessions: Endpoints for completing knowledge base for each virus family

Breakout Sessions: Spillover and ANL Collaboration

3:30 PM Coffee Break

19 Summary from breakout groups and meeting closure